Shijiazhuang Yishengtang Medical Product Co., Ltd.
MORE +
Shijiazhuang Yishengtang Medical Product Co., Ltd.
MORE +
scroll down

PRODUCTS


Main products include intraoperative hemostasis, anti-adhesion materials, wound repair dressing, trauma first aid, daily protective repair and other products.

Stop Bleeding and Prevent Adhesion


When compression, binding or other routine hemostasis measures are ineffective or cannot be implemented during surgery, hemostasis of blood capillary, vein and arteriole in the body and bleeding of surgical wound.

VIEW MORE +

Wound Tissue Repair


It is applicable to the repair of human skin and open wounds, including burns, frostbite, trauma and ulcers. Can be washed, sprayed, wet applied...

VIEW MORE +

Trauma First Aid


It is applicable to emergency hemostasis of various traumatic bleeding (such as abrasion, vascular puncture, tube insertion, incision wound, etc.)

VIEW MORE +

Daily Protection and Repair


It is suitable for disinfection of intact skin, damaged skin and wound; It is applicable to disinfection of object surface and fabric.

VIEW MORE +

YISHENGTANG MEDICAL PRODUCT

For The Health Of Millions Of Lives

View Details
2004 Year

Established

35000 ㎡

Area Covered

22 million

Registered Capital

308 +

Company Staff

Corporate Culture


Our Vision

Be a leading enterprise of biomedical materials and create outstanding brands in the industry

View Details

Management Idea

User-oriented, quality first, lean production and safety first.

View Details

Management

Crisis awareness, set an example, be honest, do things with integrity, and attach importance to talents.

View Details

Working Philosophy

Absolute obedience, dedication, results-oriented, efficient implementation, and teamwork.

View Details

BLOG CENTER


2026

11-17

news

Hemostasis and Adhesion Prevention: 2026 Evidence-Based Surgical Guide

This 2026 evidence-based guide breaks down core clinical principles, implementation workflows, and product selection criteria for hemostasis and adhesion prevention across general, gynecological, and orthopedic surgical procedures. Drawing on 3 years of real-world surgical case data from Yishengtang clinical partners, the content compares traditional gauze-based methods with modern absorbable barrier products, outlines standardized on-surgery steps, and addresses common clinical pain points to reduce post-operative complication rates for patients.

2026

11-16

news

2026 Evidence Guide: Hemostasis and Adhesion Prevention Best Practices

This evidence-based 2026 guide breaks down integrated hemostasis and adhesion prevention strategies for general, obstetric, and minimally invasive surgical teams. We draw on 10+ years of clinical product deployment data, peer-reviewed surgical safety research, and real-world case observations to compare current product options, outline standardized implementation steps, and highlight key outcome metrics that drive lower post-surgical complication rates. Content is structured to support both surgical teams evaluating new protocols and procurement teams selecting high-value, clinically validated products.

2026

11-16

news

Hemostasis and Adhesion Prevention: 2026 Evidence-Based Surgical Practice Guide

This comprehensive 2026 guide distills peer-reviewed clinical data and on-the-ground surgical experience to demystify integrated hemostasis and adhesion prevention workflows for general, gynecologic, orthopedic, and cardiac surgical teams. It breaks down product performance benchmarks, evidence-based application steps, common clinical pitfalls, and emerging best practices, drawing on 10+ years of real-world use of Yishengtang’s intraoperative hemostatic and barrier products to deliver actionable, E-E-A-T aligned guidance for clinical decision-making.

2026

11-15

news

Hemostasis and Adhesion Prevention: 2026 Clinical Guide for Surgical Teams

This 2026 evidence-based guide breaks down core principles, implementation protocols, and product selection criteria for hemostasis and adhesion prevention across general, gynecological, orthopedic, and abdominal surgical specialties. Drawing on 12+ years of clinical application data from Yishengtang’s intraoperative product line, the guide compares leading bioresorbable solution performance, outlines standard application workflows, and addresses common clinical pain points that drive post-surgical adhesion-related complications. It is designed for practicing surgeons, surgical room nurses, and clinical procurement teams seeking to reduce post-op readmission rates.

2026

11-14

news

2026 Evidence-Based Guide to Hemostasis and Adhesion Prevention: Protocols to Cut Surgical Complications

This 2026 evidence-based guide breaks down integrated hemostasis and adhesion prevention frameworks for general, gynecological, orthopedic, and cardiac surgical settings. We draw on peer-reviewed clinical data, 12 years of intraoperative product deployment experience, and head-to-head material performance comparisons to help surgical teams select appropriate barrier products, apply standardized techniques, and reduce avoidable post-surgical complications without extending operating room time.

2026

11-13

news

Hemostasis and Adhesion Prevention: 2026 Evidence-Based Surgical Practice Guide

This 2026 expert guide breaks down the clinical principles, evidence-backed protocols, and modern material innovations linking effective hemostasis to long-term adhesion prevention across general, gynecologic, orthopedic, and thoracic surgery. Drawing on real-world case data and peer-reviewed trials, the guide helps care teams reduce blood loss, cut adhesion reformation rates, and lower patient readmission risks without adding unnecessary procedural time.